Access through your institution

通过您的机构访问

Buy or subscribe

购买或订阅

The standard-of-care (SOC) first-line treatment for patients with recurrent or metastatic cervical cancer is chemotherapy with a platinum-based agent and paclitaxel, with or without bevacizumab, and with addition of an anti-PD-1 antibody in those with a PD-L1 combined positive score (CPS) ≥1. Now, data from the phase III COMPASSION-16 trial show that addition of the PD-1 × CTLA4 bispecific antibody cadonilimab to chemotherapy plus bevacizumab improves outcomes in this setting.In this trial, conducted in China, 445 women were randomly allocated (1:1) to receive first-line chemotherapy with or without bevacizumab plus either cadonilimab or placebo.

复发或转移性宫颈癌患者的标准治疗（SOC）一线治疗是使用铂类药物和紫杉醇进行化疗，有或没有贝伐单抗，并在PD-L1联合阳性评分（CPS）≥1的患者中添加抗PD-1抗体。现在，来自III期CISIC-16试验的数据显示，在化疗加贝伐单抗中加入PD-1×CTLA4双特异性抗体cadonilimab可以改善这种情况下的结果。在这项在中国进行的试验中，445名女性被随机分配（1:1）接受一线化疗，有或没有贝伐单抗加卡多尼单抗或安慰剂。

Progression-free survival (PFS) and overall survival (OS) were the co-primary end points..

无进展生存期（PFS）和总生存期（OS）是共同的主要终点。。

This is a preview of subscription content, access via your institution

这是订阅内容的预览，可通过您的机构访问

Access options

访问选项

Access through your institution

通过您的机构访问

Access through your institution

通过您的机构访问

Change institution

变革机构

Buy or subscribe

购买或订阅

Access Nature and 54 other Nature Portfolio journalsGet Nature+, our best-value online-access subscription24,99 € / 30 dayscancel any timeLearn moreSubscription info for Chinese customersWe have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.Go to naturechina.comBuy this articlePurchase on SpringerLinkInstant access to full article PDFBuy nowPrices may be subject to local taxes which are calculated during checkout.

Access Nature和54篇其他Nature Portfolio journalsGet Nature+，我们最有价值的在线订阅24,99欧元/30天，随时为中国客户获取更多订阅信息我们为中国客户提供了一个专门的网站。请访问naturechina.com订阅本期刊。访问naturechina.comBuy本文在Springerlink上购买即时访问完整文章PDFBuy now价格可能需要缴纳结帐时计算的地方税。

Additional access options:

其他访问选项：

Log in

登录

Learn about institutional subscriptions

了解机构订阅

Read our FAQs

阅读我们的常见问题

Contact customer support

联系客户支持

ReferencesOriginal articleWu, X. et al. Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China. Lancet https://doi.org/10.1016/S0140-6736(24)02135-4 (2024)Article .

参考文献Original articleWu，X。等人。卡多尼单抗加铂类化疗联合或不联合贝伐单抗作为持续性，复发性或转移性宫颈癌的一线治疗（CISIC-16）：一项随机，双盲，安慰剂对照的中国3期试验。柳叶刀https://doi.org/10.1016/S0140-6736（24）02135-4（2024）条。

PubMed

PubMed

Google Scholar

谷歌学者

Download referencesAuthor informationAuthors and AffiliationsNature Reviews Clinical Oncology http://www.nature.com/nrclinoncDiana RomeroAuthorsDiana RomeroView author publicationsYou can also search for this author in

下载参考文献作者信息作者和附属机构临床肿瘤学评论http://www.nature.com/nrclinoncDianaRomeroAuthorsDiana Romerview作者出版物您也可以在

PubMed Google ScholarCorresponding authorCorrespondence to

PubMed谷歌学者通讯社

Diana Romero.Rights and permissionsReprints and permissionsAbout this articleCite this articleRomero, D. Cadonilimab is effective and safe in recurrent cervical cancer.

戴安娜·罗梅罗。权利和许可打印和许可本文引用本文Romero，D。Cadonilimab对复发性宫颈癌有效且安全。

Nat Rev Clin Oncol (2024). https://doi.org/10.1038/s41571-024-00962-3Download citationPublished: 25 October 2024DOI: https://doi.org/10.1038/s41571-024-00962-3Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

Nat Rev Clin Oncol（2024）。https://doi.org/10.1038/s41571-024-00962-3Download引文发布日期：2024年10月25日OI：https://doi.org/10.1038/s41571-024-00962-3Share本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供